Related references
Note: Only part of the references are listed.Harnessing big data to characterize immune-related adverse events
Ying Jing et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2022)
Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study
Jianming Shen et al.
FRONTIERS IN IMMUNOLOGY (2022)
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Ryan J. Sullivan et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Visual Analysis of Colorectal Cancer Immunotherapy: A Bibliometric Analysis From 2012 to 2021
Long Ma et al.
FRONTIERS IN IMMUNOLOGY (2022)
Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021
Zhanpeng Ou et al.
FRONTIERS IN IMMUNOLOGY (2022)
Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis
Yanhao Liu et al.
FRONTIERS IN IMMUNOLOGY (2022)
Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
Alexandra Pender et al.
CLINICAL CANCER RESEARCH (2021)
Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
Joosje C. Baltussen et al.
CANCERS (2021)
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
Melissa L. Bastacky et al.
FRONTIERS IN ONCOLOGY (2021)
Global Trends in Research of Macrophages Associated With Acute Lung Injury Over Past 10 Years: A Bibliometric Analysis
Sheng Wang et al.
FRONTIERS IN IMMUNOLOGY (2021)
A Bibliometric Analysis of Pyroptosis From 2001 to 2021
Dan Ma et al.
FRONTIERS IN IMMUNOLOGY (2021)
Web of Science (WoS) and Scopus: The Titans of Bibliographic Information in Today's Academic World
Raminta Pranckute
PUBLICATIONS (2021)
Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution
R. Kleef et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer
Ane Marie Anderson et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2019)
Citations, Citation Indicators, and Research Quality: An Overview of Basic Concepts and Theories
Dag W. Aksnes et al.
SAGE OPEN (2019)
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis
Daniel Y. Wang et al.
JAMA ONCOLOGY (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Citation-based clustering of publications using CitNetExplorer and VOSviewer
Nees Jan van Eck et al.
SCIENTOMETRICS (2017)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J. M. Michot et al.
EUROPEAN JOURNAL OF CANCER (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. dbj Johnson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
Luis H. Camacho
CANCER MEDICINE (2015)
The relationship between the research performance of scientists and their position in co-authorship networks in three fields
Maria Bordons et al.
JOURNAL OF INFORMETRICS (2015)
The expansion of Google Scholar versus Web of Science: a longitudinal study
Joost C. F. de Winter et al.
SCIENTOMETRICS (2014)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Software survey: VOSviewer, a computer program for bibliometric mapping
Nees Jan van Eck et al.
SCIENTOMETRICS (2010)
A bibliometric analysis of communication journals from 2002 to 2005
Thomas Hugh Feeley
HUMAN COMMUNICATION RESEARCH (2008)
CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature
CM Chen
JOURNAL OF THE AMERICAN SOCIETY FOR INFORMATION SCIENCE AND TECHNOLOGY (2006)
Mesenchymal stem cells induce apoptosis of activated T cells
J Plumas et al.
LEUKEMIA (2005)